Common Cold Pipeline Insight 2025: Targeting Broad-Spectrum Antivirals and Host Immunity in the Fight Against Rhinovirus Infections | DelveInsight

DelveInsight's "Common Cold - Pipeline Insight, 2025" offers a thorough examination of the global R&D efforts targeting one of the most widespread yet medically under-prioritized infections: the common cold. Predominantly caused by rhinoviruses, but also by coronaviruses, RSV, and other seasonal viruses, the common cold presents a high global disease burden in terms of lost productivity and healthcare visits, despite being self-limiting in most cases.

The complexity of developing effective therapeutics stems from the etiological heterogeneity and the rapid mutational rate of cold-causing viruses. Current treatments are limited to symptomatic relief (decongestants, antihistamines, NSAIDs), with no FDA-approved antivirals specific to the common cold. However, pipeline activity is gradually gaining traction, driven by innovations from pandemic-era antiviral research and host-directed therapies.

Emerging candidates in the pipeline are focused on broad-spectrum antivirals that can block viral entry or replication across multiple viral strains. Notably, compounds targeting host-cell receptors (like ICAM-1), RNA polymerase inhibitors, and protease inhibitors are under evaluation. Parallel efforts are underway to explore immune-modulating agents and interferon-based therapies that enhance the innate immune response and reduce viral shedding.

Inhaled formulations and nasal sprays are being pursued as frontline delivery methods for their rapid onset and localized effect, with several intranasal prophylactics in early-phase trials. Additionally, repurposing of antiviral drugs originally designed for influenza, COVID-19, or RSV is a growing area of interest, especially in high-risk populations such as the elderly, asthmatic individuals, and those with compromised immunity.

With increasing recognition of the socio-economic impact of the common cold and greater interest in preparedness for respiratory viral threats, the drug development landscape is evolving. As broad-spectrum antivirals and immune-targeted interventions gain momentum, the pipeline for common cold therapeutics is poised to move beyond palliative care and toward a new standard of viral infection management.

Interested in learning more about the current treatment landscape and the key drivers shaping the common cold pipeline? Click here: https://www.delveinsight.com/report-store/common-cold-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Common Cold Pipeline Report
• DelveInsight's common cold pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for common cold treatment.
• The leading common cold companies include Sanotize Research and Development, Orbis Biosciences, Exscientia, EURRUS Biotech, and others are evaluating their lead assets to improve the common cold treatment landscape.
• Key common cold pipeline therapies in various stages of development include Nitric oxide, Guaifenesin extended release, ORB 110, IMP 1088, XC8, and others.
• In February 2025, Lupin received FDA approval for its generic version of Boehringer Ingelheim's Atrovent Nasal Spray, 0.06%. The ipratr0pium bromide nasal solution is approved for symptomatic relief of rhinorrhea due to the common cold or seasonal allergic rhinitis in adults and children aged five and older.

Request a sample and discover the recent breakthroughs happening in the common cold pipeline landscape at https://www.delveinsight.com/report-store/common-cold-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Common Cold Overview
The common cold is a viral upper respiratory tract infection that affects millions of people worldwide each year. It is primarily caused by rhinoviruses but can also be triggered by other viruses such as coronaviruses, RSV, and adenoviruses. Symptoms typically include a runny or stuffy nose, sore throat, cough, sneezing, mild headache, and fatigue.

While usually mild and self-limiting, the common cold can lead to complications in vulnerable populations such as young children, the elderly, or those with weakened immune systems. There is no cure, and treatment focuses on symptom relief through rest, hydration, decongestants, and over-the-counter medications.

Preventative measures include proper hand hygiene, avoiding close contact with infected individuals, and strengthening the immune system through a healthy lifestyle. Research is ongoing into antiviral therapies and vaccines to reduce the global burden of the common cold.

Find out more about common cold medication at https://www.delveinsight.com/report-store/common-cold-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Common Cold Treatment Analysis: Drug Profile
XC-8: EURRUS Biotech
EURRUS Biotech is developing XC-8 (histamine glutarimide), an oral therapy aimed at treating asthma, the common cold, and other acute respiratory viral infections. Phase II results indicate high efficacy with no reported side effects. XC-8 is intended for long-term use in mild to moderate asthma to help reduce dependence on corticosteroids.

Learn more about the novel and emerging common cold pipeline therapies at https://www.delveinsight.com/report-store/common-cold-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Common Cold Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous

By Molecule Type
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Common Cold Pipeline Report
• Coverage: Global
• Key Common Cold Companies: Sanotize Research and Development, Orbis Biosciences, Exscientia, EURRUS Biotech, and others.
• Key Common Cold Pipeline Therapies: Nitric oxide, Guaifenesin extended release, ORB 110, IMP 1088, XC8, and others.

To dive deep into rich insights for drugs used for common cold treatment, visit: https://www.delveinsight.com/report-store/common-cold-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Common Cold Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Common Cold Pipeline Therapeutics
6. Common Cold Pipeline: Late-Stage Products (Phase III)
7. Common Cold Pipeline: Mid-Stage Products (Phase II)
8. Common Cold Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.